STOCK TITAN

Zomedica Corp Stock Price, News & Analysis

ZOM OTC

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Zomedica Corp (NYSE American: ZOM) delivers innovative veterinary health solutions through advanced diagnostics and therapeutic technologies for companion animals and equines. This dedicated news hub provides investors and veterinary professionals with timely updates on corporate developments directly impacting animal healthcare innovation.

Access official press releases covering product launches, financial results, and strategic partnerships that shape Zomedica's position in veterinary medicine. Our curated collection ensures transparent access to regulatory filings, technology advancements, and market expansion initiatives without promotional bias.

Key updates on Zomedica's diagnostic platforms including TRUFORMA® assays, therapeutic device innovations, and clinical validation studies. Monitor operational milestones affecting veterinary practice efficiencies and animal health outcomes through verified corporate communications.

Bookmark this page for streamlined access to Zomedica's latest developments. Combine regular visits with professional financial advice when making investment or practice management decisions related to veterinary healthcare technologies.

Rhea-AI Summary

Zomedica (OTCQB:ZOMDF) has announced a strategic sponsorship agreement between its PulseVet shock wave device and the World Equestrian Center - Ocala (WEC), establishing PulseVet as the official shock wave therapy provider at the venue. The partnership includes comprehensive brand visibility through arena signage, digital promotions, and features in WEC publications.

The collaboration aims to enhance veterinary care for elite equine athletes by providing non-invasive shock wave therapy for musculoskeletal injuries. The agreement includes on-site educational resources, promotional materials, and hospitality privileges during WEC events, including discounted lodging and VIP access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

Zomedica (OTCQB:ZOMDF) has been granted a new U.S. Patent (No. 12,299,917 B2) for its TRUVIEW microscope, specifically covering Methods and Systems for Slide Imaging Calibration. The patent strengthens the company's intellectual property portfolio, which now comprises 77 U.S. patents, 144 international patents, 33 U.S. trademarks, and 107 foreign trademarks.

Bill Campbell, VP of Imaging Systems and TRUVIEW's inventor, emphasized the patent's significance in validating their focusing system innovation. CEO Larry Heaton highlighted how this protection enables continued investment in market expansion while maintaining product uniqueness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zomedica Corp. (ZOM) has announced its upcoming Fourth Friday at Four webinar, scheduled for June 27, 2025, at 4:00 PM ET. The webinar will focus on the company's TRUFORMA diagnostic platform, an in-clinic system designed for point-of-care veterinary diagnostics. The TRUFORMA system enables veterinarians to perform precise, rapid, and reliable testing without relying on external labs. The webinar will include platform demonstrations, expert insights on diagnostic workflow transformation, case studies of improved patient outcomes, and an interactive Q&A session with Zomedica's leadership and technical experts. CEO Larry Heaton emphasizes the company's commitment to empowering veterinarians with tools that enhance diagnostic capabilities while improving practice efficiency and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Zomedica (OTCQB:ZOMDF) has announced significant enhancements to its equine insulin assay for the TRUFORMA Diagnostic Platform. The update features an extended dynamic range, increased by 60% from its previous version, and introduces an innovative automatic sample dilution function. This advancement allows veterinarians to measure insulin levels at the highest ranges without additional steps or increased time-to-result.

The new automatic dilution feature eliminates the need for manual dilution protocols for samples exceeding 250 µU/mL, streamlining the testing process. The enhancement maintains test consistency while freeing staff from additional tasks. This development positions TRUFORMA as having the widest dynamic range available both at Point of Care and compared to Reference Labs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.

The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.

Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Zomedica Corp (NYSE American:ZOM) announced its delisting from the NYSE American exchange and transition to the OTCQB Venture Market, effective March 5, 2025. The company's ticker symbol will change to ZOMDF.

The delisting is due to the NYSE American's determination that Zomedica no longer meets listing requirements under Section 1003(f)(v) of the Company Guide, specifically citing the low selling price of common shares. Despite this change, Zomedica will maintain SEC reporting requirements and continue providing real-time trading data and financial disclosures through OTC Markets.

CEO Larry Heaton emphasized that while disappointed with the delisting, the company's asset value and growth opportunities remain unchanged, with continued focus on developing veterinary products and maintaining investor engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Zomedica (NYSE American:ZOM) has scheduled its Fourth Quarter and Full Year 2024 Financial Results conference call and audio webcast for March 13, 2025, at 4:30 p.m. ET. The veterinary health company, which specializes in point-of-care diagnostic and therapeutic products for equine and companion animals, will present operational and financial highlights followed by a Q&A session.

Interested participants can join via phone at +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International). A replay will be available until March 27, 2025, at 11:59 PM ET by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) with pin number: 1174148.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
conferences earnings
-
Rhea-AI Summary

Zomedica (NYSE American:ZOM) has relocated its corporate headquarters within Ann Arbor, Michigan, marking a strategic move to improve operational efficiency and reduce costs. The new facility, which replaced their previous Phoenix Drive location after its lease expired on January 31, 2025, represents a 19% reduction in square footage and a 50% reduction in base annual rent.

This relocation is expected to generate over $200,000 in annual cost savings while providing a modernized workspace for the company's growing team. According to management, the move aligns with Zomedica's strategy to achieve profitability by optimizing resources while maintaining investment in innovation and growth. The freed-up capital will be reinvested into the business to accelerate the company's path to financial sustainability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
Rhea-AI Summary

Zomedica (NYSE:ZOM) has announced a significant update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. The enhanced test, initially launched in September 2024, now measures both full-length endogenous ACTH and CLIP (Corticotropin-Like Intermediate Peptide), providing a composite value comparable to traditional laboratory results.

The advancement represents a potential breakthrough in diagnosing Pituitary Pars Intermedia Dysfunction (PPID), a common equine endocrine disorder. The updated assay is particularly notable as it's the first to enable simultaneous measurement of both CLIP and full-length ACTH in a clinical setting, offering veterinarians a more comprehensive diagnostic tool at the point-of-care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.0973 as of April 29, 2025.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 120.4M.
Zomedica Corp

OTC:ZOM

ZOM Rankings

ZOM Stock Data

120.44M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR